No Photo Available

Last Update

2017-02-01T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong William Ludlam?

Dr. William H. Ludlam

Vice President Medical Affairs

Chiasma Inc.

HQ Phone: (617) 928-5300

Email: w***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Chiasma Inc.

60 Wells Ave Ste 102

Newton, Massachusetts 02459

United States

Company Description

Chiasma is a biopharma company focused on creating new drug products by marrying its proprietary technology to approved drugs. This enables drugs to be switched from injectable to oral, but importantly can also result in new indications or improved labels ... more

Find other employees at this company (74)

Background Information

Employment History

Medical Director

Pituitary Network Association

Program Director

Swedish Cancer Institute

Senior Medical Director

Novartis AG

Affiliations

Member
American Association of Clinical Endocrinologists Inc

Member
The Endocrine Society

Education

Medical School at Albert Einstein College of Medicine , NY

M.D.

MS

Web References (73 Total References)


Management Team | Chiasma

www.chiasma.com [cached]

William Ludlam, MD, PhD

Senior VP Clinical Development and Medical Affairs


William Ludlam, MD, ...

www.chiasma.com [cached]

William Ludlam, MD, PhD

William Ludlam, M.D., Ph.D., is currently Chiasma's Sr. VP Clinical Development and Medical Affairs. He joined Chiasma as VP Medical Affairs in August 2015. Dr. Ludlam came to us from Novartis Pharmaceuticals, where he was Senior Medical Director, Pituitary Disorders, US Oncology CDMA, Rare Diseases. Earlier, he served as Medical Director of the Seattle Pituitary Center, Neuroscience Institute, Swedish Medical Center, and as Medical Director of the Pituitary Unit, Oregon Health and Science University. He has also held academic appointments at the Oregon Health and Science University. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists, and serves on the Hormone Health Network of the Endocrine Society. Dr. Ludlam earned his MS and PhD from the Sue Golding Graduate Division of the Albert Einstein College of Medicine and his MD from the Albert Einstein College of Medicine.


Press Release | Chiasma

ir.chiasmapharma.com [cached]

William H. Ludlam , M.D., Ph.D., as Vice President of Medical Affairs.

...
Dr. Ludlam came to Chiasma from Novartis Pharmaceuticals Corporation , where he served most recently as Senior Medical Director for


New additions to the team include ...

www.biospace.com [cached]

New additions to the team include Anand Varadan as Chief Commercial Officer and William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs.

...
Dr. Ludlam came to Chiasma from Novartis Pharmaceuticals Corporation, where he served most recently as Senior Medical Director for U.S. Clinical Development and Medical Affairs, Pituitary Disorders, Rare Diseases Franchise.


Press Release | Chiasma

ir.chiasmapharma.com [cached]

Chiasma Appoints William H. Ludlam, M.D., Ph.D., as Vice President of Medical Affairs

...
William H. Ludlam
...
Dr. Ludlam, a highly-regarded academic leader in the pituitary and rare disease space, comes to Chiasma after spending the last four years at Novartis Pharmaceuticals , where he served most recently as Senior Medical Director for the U.S. Clinical Development and Medical Affairs (USCDMA), Pituitary Disorders, Rare Diseases Franchise. Novartis is currently a leading seller of injectable octreotide, one of the standard treatment options for patients suffering from acromegaly.
In his role at Chiasma, Dr. Ludlam will be responsible for developing strategy around clinical and technical information to support the planned commercial launch of Mycapssa™ for the maintenance treatment of adults with acromegaly. He will also lead all medical review activities around the Company's product education campaign, including its presence at key scientific events. In
...
"Dr. Ludlam's extensive academic and industry experience in the rare disease space, particularly pituitary disorders, makes him an ideal choice to help lead the medical strategy for our anticipated launch of Mycapssa™ in 2016," said
...
"Dr. Ludlam has worked firsthand with acromegaly patients, both in his current role at
...
in 2012, Dr. Ludlam spent 15 years in a number of academic and clinical roles. From 2007 to 2011, he served as medical director at the Seattle Pituitary Center within the Neuroscience Institute at the Swedish Medical Center , and from 2002 to 2006 as medical director of the Pituitary Unit at the Oregon Health and Science University . Dr. Ludlam helped develop both treatment centers and conducted clinical research for novel treatment options for pituitary disorders while actively treating patients with acromegaly and Cushing's disease, among other conditions.
Dr. Ludlam holds an M.D. and Ph.D. from the
...
"I am extremely pleased to be joining Chiasma prior to the potential launch of Mycapssa™," said Dr. Ludlam.

Similar Profiles

Other People with this Name

Other people with the name Ludlam

Jay Ludlam
Missouri Department of Conservation

Carolyn Ludlam
Ergon Inc

Gina Ludlam
Chase Professionals

Clare Ludlam
Taylor Wessing LLP

Martyn Ludlam
Greenyard Fresh UK Ltd

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory